Pills masthead

News Releases

Archives: Search / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

201020092008200720062004

Jan 13, 2020
--Company to Commence Commercial Launch Shortly, Under Brand Name NUMBRINO®--

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway,...

More
Jan 6, 2020

Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The...

More
Dec 23, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Butalbital,...

More
Dec 12, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to commence marketing in the coming months a generic version of Adderall XR®, an extended-release mixed salt of a single entity...

More
Dec 4, 2019
--Study Achieves All Primary Endpoints; Company to Set Meeting with FDA Regarding Pivotal Trial Design--

Lannett Company, Inc. (NYSE: LCI) today announced positive results from the first human study evaluating insulin glargine that Lannett is developing with its strategic alliance partners within the...

More
Nov 6, 2019

Financial and Business Highlights: Net Sales, Profitability Exceeded Expectations Launched First-to-Market Posaconazole Expanded Pipeline with Significant Future Opportunities: • Levothyroxine...

More
Oct 30, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 first quarter on Wednesday, November 6, 2019, after the market closes. Lannett...

More
Oct 1, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of ADVAIR DISKUS® (Fluticasone...

More
Sep 27, 2019

Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the closing of $86.25 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in...

More
Sep 25, 2019

Lannett Company, Inc. (NYSE: LCI) ("Lannett" or the "Company") today announced the pricing of $75 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the "Notes") in a...

More
 
Price Data
NYSELCI